17:50 , Oct 19, 2018 |  BC Week In Review  |  Financial News

Equillium prices $65.4M IPO

Autoimmune and inflammatory disease company Equillium Inc. (NASDAQ:EQ) raised $65.4 million in an IPO on Oct. 12 through the sale of 4.7 million shares at $14. Jefferies, Leerink and Stifel underwrote the offering. The company...
16:19 , Oct 4, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer Mouse studies suggest CAR T cells targeting ALCAM and HER2 could help treat brain cancer. The cells are generated by conjugating T cells expressing HER2-targeting CARs to a construct consisting of pentamers...
16:32 , Sep 21, 2018 |  BC Week In Review  |  Financial News

Equillium proposes $86.3M IPO

Autoimmune and inflammatory disease company Equillium Inc. (La Jolla, Calif.) proposed to raise up to $86.3 million on Sept. 17 in an IPO on NASDAQ underwritten by Jefferies, Leerink and Stifel. The company has U.S....
22:56 , Sep 5, 2018 |  BC Extra  |  Preclinical News

Two papers open door to T cell brain entry for glioblastoma therapy

Two new studies have proposed solutions to different barriers that prevent T cells from entering the brain to attack glioblastoma. Glioblastoma patients often have low T cell counts, and their tumors’ ability to evade immune...
23:39 , Aug 2, 2017 |  BC Extra  |  Preclinical News

CDCP1 identified as potential autoimmune target

In a paper published in...
19:07 , Feb 22, 2017 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Multiple sclerosis (MS) Mouse studies suggest inhibiting CD6 could help treat MS. In an experimental autoimmune encephalomyelitis (EAE) mouse model of MS, CD6 knockout decreased clinical signs of encephalomyelitis and T cell infiltration in...
08:00 , Nov 12, 2015 |  BC Innovations  |  Product R&D

Probodies, anticancer

Lauren Martz, Senior Writer  How successful checkpoint inhibitors and chimeric antigen receptor (CAR) T cells will be at revolutionizing oncology hangs largely on whether it will be possible to curb their on-target but off-tissue toxicities....
07:00 , Apr 16, 2015 |  BC Innovations  |  Product R&D

Antagonizing psoriasis

Despite the heavy competition in psoriasis, AnaptysBio Inc. believes it can make a mark with a first-in-class antibody for a neglected, inherited form of pustular psoriasis caused by a loss-of-function mutation in the proinflammatory cytokine...
07:00 , Sep 16, 2013 |  BioCentury  |  Strategy

Alzumab's (re)mission statement

Biocon Ltd. is betting the long remission time and reduced opportunistic infections associated with its Alzumab itolizumab will pull doctors away from biologics with better efficacy in psoriasis. The company has long maintained that the...
07:00 , Aug 19, 2013 |  BC Week In Review  |  Company News

Biocon sales and marketing update

Biocon launched Alzumab itolizumab in India to treat chronic plaque psoriasis. Biocon said the price for a 25 mg/5 mL vial of Alzumab is Rs7,950 ($131) and that the recommended dose is 1.6 mg/kg, with...